Barcelona-based biotech startup Biorce helps speed up clinical trials using AI and has raised €5 million in new funding, bringing its total funding to €8.5 million.
- Biorce was founded in 2022 in Barcelona by Pedro Coelho, Diogo Pisoeiro, Clara Bernardes, and José Faria. The company develops Jarvis, an AI-powered assistant built specifically for clinical research.
- Jarvis supports pharmaceutical companies, biotech firms, and clinical research organizations (CROs) in designing and managing trials more efficiently.
- Trained on data from over 500,000 clinical studies, the platform helps with protocol design, feasibility checks, regulatory alignment, endpoint selection, and patient recruitment.
- It provides real-time, evidence-backed insights to reduce delays and operational errors, without replacing expert judgment. Biorce’s tools aim to cut costs, minimize amendments, and accelerate the process of bringing new drugs to market. The platform also includes features that help patients and physicians find and match with relevant clinical trials.
“We’re tackling the root causes of delay and inefficiency in clinical trials: issues that cost time, money, and ultimately lives. Our solution cuts through complexity, shortens timelines, and improves outcomes for patients," founder and CEO of Biorce, Pedro Coelho, commented.
- In November 2024, Biorce raised €3.5 million in a seed round led by YZR Capital and Mustard Seed Maze. The funding helped Biorce improve its AI platform Jarvis, hire more staff, enhance real-time data features for patients, doctors, and researchers, and expand into new markets.
Details of the deal
- The recent funding was provided by Norrsken VC, a Stockholm-based venture capital firm classified as an SFDR Article 9 ("Dark Green") fund. Their investments are linked to at least one of the 17 Sustainable Development Goals, and they work closely with startups to track and expand their impact.
“Biorce is exactly the kind of pioneering company we’re here to back. They’re combining deep sector expertise with cutting-edge AI to solve what truly matters. Their platform has the potential to radically reduce both the time and cost of bringing new treatments to market, unlocking huge value for pharma and, more importantly, faster access to life-saving therapies for patients," claims Tove Larsson, General Partner at Norrsken VC.
- Biorce plans to use the fresh €5 million funding to expand into the US market, grow their engineering and sales teams, accelerate product development of their AI platform Jarvis, and increase revenue toward eight-digit figures.
